An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
Completed · Phase 3 · NCT05514873
Conditions: Generalized Myasthenia Gravis
At a glance
- Research payments reported, 2025
- $205,833
- U.S. investigators named
- 11
- Sites paid
- 11
- Planned or actual enrollment
- 26
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- zilucoplan (RA101495) (drug)
- Dates
- Started 2022-10-31; completion 2024-10-23
- Results posted
- Yes
The purpose of the study is to evaluate the safety and tolerability of switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) Zilucoplan in study participants with generalized myasthenia gravis (gMG)
From ClinicalTrials.gov, last updated 2025-09-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $205,833 in research payments for this study in 2025 (11 payments).
Products named: Zilbrysq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Todd D. Levine, MD Neurology · Phoenix, AZ
- Perry B. Shieh, MD Neurology · Los Angeles, CA
- Michael H. Rivner, MD Neurology · Macon, GA
- Raghav Govindarajan, MD Physical Medicine & Rehabilitation (PM&R) · O Fallon, IL
- Min K. Kang, MD Neurology · Boston, MA
- Urvi G. Desai, MD Neurology · Charlotte, NC
- James Howard, MD Neurology · Chapel Hill, NC
- Bakri H. Elsheikh, MD Neurology · Columbus, OH
- Shaida Khan, D.O. Neurology · Dallas, TX
- Michael D. Weiss Neurology · Seattle, WA
- Bhupendra O. Khatri, M.D. Neurology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The University of Texas Southwestern Medical Center $32,725
- Bcn Research LLC $28,786
- The Ohio State University $28,327
- Wake Forest University Health Sciences $28,075
- University of North Carolina at Chapel Hill $27,696
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $17,821
- University of Washington Medical Ctr, WA $12,840
- Honor Health John C. Lincoln Medical Center, AZ $9,352
- Prairie Education & Research Cooperative Perc $8,316
- Ronald Reagan UCLA Medical Center, CA $7,833
- Ghsu Research Institute, Inc. $4,063
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.